CSL Behring has announced that the Australian Therapeutic Goods Administration has approved Afstyla (lonoctocog alfa) a recombinant single chain coagulation factor VIII (rFVIIISingleChain) in patients with haemophilia A (congenital factor VIII deficiency).
Afstyla is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A, the company said.
The announcement comes just 48 hours after the company had marked World Haemophilia Day on Monday 17th Apr.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Apr 17
